Reorganization helps Takeda realize globalization vision
Osaka, Japan - March 31, 2009 – Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.
“Takeda is making meaningful changes in structure and governance through this reorganization and the creation of the CSO, EVP, International Operations, and CAO roles, which we believe will further strengthen our global operations structure,” said Yasuchika Hasegawa, President, Takeda Pharmaceutical Company Limited. “Through this new organizational structure, Takeda looks forward to continuing our history of creating and marketing novel pharmaceutical products that meet the needs of patients globally.”
Details of the Reorganization
Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will assume the role of Chief Scientific Officer, responsible for global Research, Development, Chemistry Manufacturing and Controls (CMC), and Intellectual Property (IP). The creation of the CSO role provides the opportunity to further enhance product development effectiveness through the integration of research and development. The CSO will be based in the United States at Takeda’s Deerfield, Illinois headquarters and in Osaka, Japan.
Dr. Ohkawa is a member of the Takeda Board of Directors and previously was the General Manager of the Pharmaceutical Research Division. Dr. Ohkawa has been with Takeda for 30 years.
Hiroyuki Odaka, Ph.D., will replace Dr. Ohkawa as General Manager, Pharmaceutical Research Division. Dr. Odaka joined Takeda in 1982 and most recently has been Director of Pharmacology Research Laboratory 1.
Tetsuo Miwa, Ph.D. will become General Manager, CMC Center. Dr. Miwa joined Takeda in 1985 and has held a number of leadership roles in Takeda’s research organization, including Director of Discovery Research Center. Most recently, Dr. Miwa belonged to Strategic Product Planning and was in charge of cross-franchise portfolio management and the Millennium acquisition and transition.
Nancy Joseph-Ridge, M.D., will replace Dr. Masaomi Miyamoto as General Manager, Pharmaceutical Development Division. Dr. Joseph-Ridge is currently President of Takeda Global Research & Development Center, Inc., U.S., and will retain this position until her replacement has been announced. She was previously with TAP Pharmaceutical Products Inc.
Yoichi Okumura, will continue in his role as General Manager of Intellectual Property Department. Mr. Okumura joined Takeda in 1984 and has been General Manager of IP Department since 2007.
To ensure further global optimization of the company’s pharmaceutical development functions, the global development headquarter functions will be moved to Takeda’s Deerfield, Illinois headquarters in the United States, with the transfer anticipated to be complete by July 1. Previously, the Takeda Group’s headquarters for development were based in Osaka, Japan, and Takeda managed global development through its regional hubs in Japan, the United States, Europe and a recently established subsidiary in Asia.
Also effective April 1, 2009, Alan MacKenzie will assume the role of EVP, International Operations, responsible for all international (ex-Japan) commercial operations in the United States, Europe, and Asia, as well as global medical affairs and international marketing. The creation of the EVP, International Operations role enhances Takeda’s globalization efforts and allows for more streamlined commercial decision making. The EVP, International Operations will be based in the United States at Takeda’s Deerfield, Illinois headquarters.
Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals Europe Limited, and Takeda Pharmaceuticals Asia Private Limited will report to EVP, International Operations.
Formerly President and CEO of Takeda Pharmaceuticals North America, Inc. and Executive Vice President of Takeda America Holdings, Inc., Mr. MacKenzie has been with the Takeda family of companies for 24 years. He was a founding executive of Takeda Pharmaceuticals North America, Inc. and past President of TAP Pharmaceutical Products Inc.
Shinji Honda will replace Mr. MacKenzie as CEO, Takeda Pharmaceuticals North America, Inc. Mr. Honda joined Takeda in 1981 and has held a variety of roles in the global organization including Executive Vice President of TAP Pharmaceutical Products Inc. and head of the U.S. Operations Department. Most recently, Mr. Honda was the General Manager of the Overseas Business Planning Department.
Erich Brunn, Ph.D. will continue in his role as CEO of Takeda Pharmaceuticals Europe Limited. Dr. Brunn is responsible for oversight of pan-European sales and marketing. Dr. Brunn was previously President of Takeda Pharma GmbH, a wholly owned subsidiary of Takeda in Germany.
Mr. Stefan Ziegler will continue in his role as CEO of Takeda Pharmaceuticals Asia Private Limited. Mr. Ziegler is responsible for oversight of overall Asian sales and marketing. Mr. Ziegler worked at Novartis from 1990 to 2008.
In conjunction with this reorganization, Takeda has established a new wholly-owned affiliate, Takeda Pharmaceuticals International, Inc. to which the newly established roles of CSO and EVP, International Operations will belong.
Overseas Business Planning Department—which has been a support function for international marketing affiliates as they directly reported to the President, Takeda Pharmaceutical Company Limited—will be dissolved on May 1 following the establishment of the EVP International Operations role.
A CAO role is to be established and will provide comprehensive leadership for the corporate functions of Human Resources, Finance & Accounting, Legal and Corporate Communications. Through a strong understanding of each role, the CAO will promote collaboration between the corporate functions to further strengthen the Company’s global strategy.
Additionally, Millennium: The Takeda Oncology Company, will continue to be led by Deborah Dunsire, M.D., reporting directly to the President, Takeda Pharmaceutical Company Limited, and will retain all its current research, global development, global product and marketing strategies, and US commercial responsibilities in the oncology field.